Abstract:Background and Aim: Esomeprazole is the S‐isomer of omeprazole, with a stronger acid suppressive effect than omeprazole. This open, randomized crossover study was designed to evaluate the effect of esomeprazole and another proton‐pump inhibitor, rabeprazole, on intragastric pH in healthy Chinese. Methods: Thirty‐six healthy volunteers (26 men and 10 women, aged between 20 and 31 years) were enrolled. Subjects were given either esomeprazole 40 mg ( n = 18) or rabeprazole 10 mg ( n = 18) orally once daily for 5 days during the first dosing period, then the other medicine at the set dosage for the second dosing period. The two periods were separated by a 14‐day washout phase. The doses were chosen according to the State Food and Drug Administration of China for the treatment of acid‐related diseases. Intragastric pH was continuously monitored for 24 h on days 1 and 5 of each dosing period. CYP2C19 genotypes were analyzed to identify the extensive metabolizers (EM) and poor metabolizers (PM). Results: The percentage of time with intragastric pH >4 was significantly higher ( P < 0.001) in subjects receiving esomeprazole than in those receiving rabeprazole in the first 4 h after administration of the first dose (70.65% vs 44.87%), at 24 h on day 1 (73.7% vs 54.8%) and at 24 h on day 5 (84.2% vs 76.2%). The median intragastric pH was also higher in subjects receiving esomeprazole than in those receiving rabeprazole in the first 6 h, day 1 and day 5 ( P ≤ 0.001). The percentage of subjects with intragastric pH >4 for at least 16 h on day 1 (63.9% vs 33.3%) and on day 5 (88.9% vs 61.1%) was higher after administration of esomeprazole than after rabeprazole (both P < 0.05). On genotype analysis, 28 of the subjects were EM and eight were PM. Those who were PM tended to have a higher, albeit not statistically significant, percentage of time with intragastric pH >4 and the median 24‐h intragastric pH than those who were EM. Both drugs were well tolerated. Conclusions: Esomeprazole 40 mg orally once daily is more effective and faster in increasing intragastric pH than rabeprazole 10 mg orally once daily, and thus offers a potential for improved efficacy in acid‐related diseases.

Esomeprazole for gastroesephageal reflux disease: a systematic review

Efficacy and Safety of Omeprazole for the Treatment of Acid Peptic Disorders: A Systematic Review and Meta-Analysis

Clinical comparison of rabeprazole and omeprazole in the treatment of reflux esophagitis

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis

A systematic review and meta‐analysis of the efficacy of vonoprazan for proton pump inhibitor‐resistant gastroesophageal reflux disease

Analysis of the Effect of Omeprazole and Tegaserod on Non-Erosive Reflux Disease

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis

Quality of Life and Cost-Effectiveness of Combined Therapy for Reflux Esophagitis.

Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis

Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis

Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis

Clinical efficacy of omeprazole combined mosapride in treating reflux esophagitis

A Systematic Review of the Treatment of Gastroesophageai Reflux Disease with Mosapride in China

Effectiveness of Rabeprazole and Other Proton Pump Inhibitors in Managing GERD with Varying Severity: A Retrospective, Real-world EMR-based Study (POWER GERD Study)

Clinicai Investigation on Esomeprazoie Treatment of Sixty-Nine Asthmatic Patients with Gastroesophageal Reflux Symptoms

Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: A protocol for meta-analysis and systematic review

Efficacy of endoscopic radiofrequency ablation for proton pump inhibitor‐dependent gastroesophageal reflux disease: Multicenter prospective cohort study